2015: AACR First Results of a 10-Day Regimen of SGI-110 in Previously Untreated Elderly AML

/in , ,

Summary

  • Elderly and unfit individuals with AML are often ineligible to receive intensive chemotherapy
  • Hypomethylating agents (HMA) such as decitabine and azacitidine have shown efficacy and acceptable safety in these patients
  • SGI-110 (guadecitabine) is a next generation HMA given as a small volume subcutaneous (SC) administration
  • We previously presented Phase 2 data of SGI-110 using the standard 5-day regimen which showed good good clinical activity in these patients
  • We present here , the preliminary results (minimum follow up of 3 months) of a 10-day regimen of SGI-110 in treatment naïve (TN) AML patients who are ineligible for intensive chemotherapy (IC)

View further details below
2015: AACR First Results of a 10-Day Regimen of SGI-110 in Previously Untreated Elderly AML